研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Tongji Hospital,Wuhan,Hubei,China,40030
研究目的：
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics. In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).
